<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287287</url>
  </required_header>
  <id_info>
    <org_study_id>05-701-F3R</org_study_id>
    <nct_id>NCT00287287</nct_id>
    <nct_alias>NCT00381498</nct_alias>
  </id_info>
  <brief_title>REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas</brief_title>
  <official_title>Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary &amp; Follicular Thyroid Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth Ain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the anti-tumor activity of REVLIMID®
      (lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid
      carcinomas which are unresponsive to systemic radioiodine, in terms of tumor response and
      response duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide has found new uses as a tumor anti-angiogenesis agent that is capable of
      diminishing the proliferation of angiogenesis-dependent solid malignancies. Distantly
      metastatic, unresectable medullary thyroid carcinomas, as well as de-differentiated papillary
      and follicular thyroid carcinomas, which no longer concentrate radioiodine, have no known
      effective systemic therapies. We have verified, in the context of a completed phase 2
      clinical trial, that thalidomide has significant activity in thyroid carcinomas that are no
      longer radioiodine avid and are rapidly progressive. This activity has only limited
      durability of around 7 months and is associated with significant toxicities of sedation,
      constipation and neuropathy.

      REVLIMID® (lenalidomide) is an analog of thalidomide with the chemical name,
      alpha-(3-aminophthalimido) glutarimide. REVLIMID® is noted to be more potent than thalidomide
      in inhibiting the production of TNF-alpha. It has more than doubled the inhibition of
      microvessel growth at the same concentration as thalidomide in a rat aorta angiogenesis model
      as well as greatly enhanced activity as an IMiD. Most importantly, it lacks much of the
      toxicity of thalidomide, particularly in regards to somnolence, neuropathy, or biochemical
      effects. In fact, patients with multiple myeloma, known to be resistant to thalidomide, were
      still seen to exhibit clinical responses to REVLIMID®. This makes REVLIMID® an appropriate
      agent to investigate in a phase 2 trial in thyroid carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Actual">July 6, 2010</completion_date>
  <primary_completion_date type="Actual">July 6, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lenalidomide (Revlimid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
    <arm_group_label>Lenalidomide (Revlimid)</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of follicular, papillary, insular, or Hürthle-cell thyroid
             carcinoma. Histologic slides and/or tissue blocks must be reviewed at the University
             of Kentucky Medical Center.

          -  Patients must have an unresectable, distantly metastatic tumor, which does not
             concentrate radioactive iodine. Alternatively, follicular or papillary thyroid
             carcinoma patients with large distant tumor burdens which have not sufficiently
             responded to more than 800 mCi I-131 cumulative therapy and are progressive (criteria
             #4) may be appropriate for inclusion.

          -  No systemic chemotherapy agents within 4 weeks of initiation of therapy.

          -  Patients must have 3 consecutive radiographic evaluations demonstrating a cumulative
             30% increase in tumor volume over a period of one year or less.

          -  Patients must be over the age of 18 years with the ability to understand and willing
             to sign an informed consent.

          -  Non-pregnant (if female). Women of childbearing potential (fertile females) must have
             a negative serum or urine pregnancy test within one day of starting study drug. In
             addition, sexually active fertile female subjects must agree to adequate contraceptive
             methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation,
             intrauterine device, barrier contraceptive with spermicide; or vasectomized partner)
             while on study drug. Men must agree to use latex condoms when having sex with fertile
             women.

          -  Karnofsky performance status ≥ 70.

          -  Baseline laboratory studies:

               -  absolute neutrophil count (ANC) &gt; 1000/mm3

               -  platelet count ≥ 100 K/mm3

               -  creatinine ≤ 1.5 mg/dL, and

               -  transaminase levels (AST/SGOT, ALT/SGPT) ≤ 2 x upper limit of normal (ULN) (or ≤
                  5 x I:M if hepatic metastases are present)

          -  Disease free of other prior malignancies for ≥ 5 years, with the exception of
             currently treated basal cell/squamous cell carcinoma of the skin or &quot;in-situ&quot;
             carcinoma of the cervix or breast.

          -  Thyroid stimulating hormone (TSH, thyrotropin) levels must be suppressed with
             sufficient levothyroxine to be kept beneath the normal range of the assay.

        Exclusion Criteria:

          -  Patients may not have had prior REVLIMID® therapy.

          -  No serious concomitant medical or psychiatric illness that might interfere with
             informed consent or conduct of the study, including active infections that are not
             controlled with medication.

          -  Patients must not be pregnant or breastfeeding.

          -  Use of any other experimental drug or therapy within 28 days of baseline.

          -  Known hypersensitivity to thalidomide.

          -  The development of erythema nodosum, characterized by a desquamating rash, while
             taking thalidomide or similar drugs.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Concurrent use of other anti-cancer agents or treatments, with the exception of
             thyrotropin-suppression by levothyroxine.

          -  All subjects with central nervous system involvement, with the exception of those
             subjects whose central nervous system metastases have been treated with either
             radiotherapy and/or surgery and remain asymptomatic with no evidence of active central
             nervous system disease (verified by computed tomography [CT] scan or magnetic
             resonance imaging [MRI]) for at least 6 months.

          -  Known to be positive for HIV or infectious hepatitis, type A, B, or C.

          -  Patients with medullary or anaplastic thyroid carcinomas are excluded. Patients whose
             disease is limited to bone metastases are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth B Ain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Kenneth Ain</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Clinical Trials phase II</keyword>
  <keyword>Carcinomas, thyroid</keyword>
  <keyword>Radioiodine-Unresponsive</keyword>
  <keyword>Papillary</keyword>
  <keyword>Follicular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT00287287/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
Lenalidomide: Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
Lenalidomide: Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide (Revlimid)</title>
            <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>Serious adverse events were defined as Grade 3 or higher.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Ain</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>8593236652</phone>
      <email>kenneth.ain@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

